KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

NovoCure (NVCR) Tax Provisions (2016 - 2026)

NovoCure's Tax Provisions history spans 13 years, with the latest figure at $1.9 million for Q1 2026.

  • On a quarterly basis, Tax Provisions fell 53.28% to $1.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$2.2 million, a 106.3% decrease, with the full-year FY2025 number at -$23000.0, down 100.06% from a year prior.
  • Tax Provisions hit $1.9 million in Q1 2026 for NovoCure, up from -$16.5 million in the prior quarter.
  • Over the last five years, Tax Provisions for NVCR hit a ceiling of $10.7 million in Q4 2024 and a floor of -$16.5 million in Q4 2025.
  • Historically, Tax Provisions has averaged $3.8 million across 5 years, with a median of $4.0 million in 2025.
  • Biggest five-year swings in Tax Provisions: soared 611.4% in 2024 and later tumbled 253.56% in 2025.
  • Tracing NVCR's Tax Provisions over 5 years: stood at $4.7 million in 2022, then skyrocketed by 80.08% to $8.5 million in 2023, then grew by 25.41% to $10.7 million in 2024, then tumbled by 253.56% to -$16.5 million in 2025, then surged by 111.43% to $1.9 million in 2026.
  • Business Quant data shows Tax Provisions for NVCR at $1.9 million in Q1 2026, -$16.5 million in Q4 2025, and $7.2 million in Q3 2025.